 Connection
Petter Bjornstad to Aged
This is a "connection" page, showing publications Petter Bjornstad has written about Aged.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.549 |
|
|
|
-
Bjornstad P, Nelson RG, Pavkov ME. Do sodium-glucose cotransporter-2 inhibitors affect renal hemodynamics by different mechanisms in type 1 and type 2 diabetes? Kidney Int. 2020 01; 97(1):31-33.
Score: 0.037
-
Bjornstad P, Lovshin JA, Lytvyn Y, Lovblom LE, Scarr D, Boulet G, Farooqi MA, Orszag A, Bai JW, Weisman A, Keenan HA, Brent MH, Paul N, Bril V, Perkins BA, Cherney DZI. Elevated plasma cyclic guanosine monophosphate may explain greater efferent arteriolar tone in adults with longstanding type 1 diabetes: A brief report. J Diabetes Complications. 2019 08; 33(8):547-549.
Score: 0.035
-
Bjornstad P, Singh SK, Snell-Bergeon JK, Lovshin JA, Lytvyn Y, Lovblom LE, Rewers MJ, Boulet G, Lai V, Tse J, Cham L, Orszag A, Weisman A, Keenan HA, Brent MH, Paul N, Bril V, Perkins BA, Cherney DZI. The relationships between markers of tubular injury and intrarenal haemodynamic function in adults with and without type 1 diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. Diabetes Obes Metab. 2019 03; 21(3):575-583.
Score: 0.034
-
Bjornstad P, Lovshin JA, Lytvyn Y, Boulet G, Lovblom LE, Alhuzaim ON, Farooqi MA, Lai V, Tse J, Cham L, Orszag A, Scarr D, Weisman A, Keenan HA, Brent MH, Paul N, Bril V, Perkins BA, Cherney DZI. Adiposity Impacts Intrarenal Hemodynamic Function in Adults With Long-standing Type 1 Diabetes With and Without Diabetic Nephropathy: Results From the Canadian Study of Longevity in Type 1 Diabetes. Diabetes Care. 2018 04; 41(4):831-839.
Score: 0.032
-
Bjornstad P, Johnson RJ, Snell-Bergeon JK, Pyle L, Davis A, Foster N, Cherney DZ, Maahs DM. Albuminuria is associated with greater copeptin concentrations in men with type 1 diabetes: A brief report from the T1D exchange Biobank. J Diabetes Complications. 2017 Feb; 31(2):387-389.
Score: 0.030
-
van Baar MJB, Bjornstad P, Touw DJ, Joles JA, Krebber MM, Cherney DZI, van Raalte DH, Muskiet MHA. Renal functional reserve predicts GFR response to empagliflozin in RENALIS and RACELINES clinical trials. Nephrol Dial Transplant. 2026 Jul 31; 41(8):1520-1528.
Score: 0.015
-
Athinarayanan SJ, Bjornstad P, Shanmugam PV, Weimbs T, Wolfberg AJ, Volek JS, Himmelfarb J, Johnson RJ. Effectiveness of Telehealth Low-Carbohydrate Intervention in Preventing Chronic Kidney Disease: A Real-World, Retrospective, Matched Cohort Study. Diabetes Obes Metab. 2026 10; 28(10):9054-9068.
Score: 0.015
-
Liu JJ, Liu S, de Keizer J, Zheng H, Lee J, Javaugue V, Gurung RL, Ang K, Potier L, Nelson RG, Kestenbaum B, Bjornstad P, Lim SC, Hadjadj S, Saulnier PJ. Fasting urine osmolality and risk of kidney disease progression in patients with type 2 diabetes. Nephrol Dial Transplant. 2026 Jun 30; 41(7):1304-1312.
Score: 0.015
-
Heerspink HJL, van Raalte DH, Bjornstad P, Bunck MC, Wu P, Tunali I, Milicevic Z, Koeneman L. Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease. Nephrol Dial Transplant. 2026 May 29; 41(6):1058-1068.
Score: 0.014
-
van Heugten MH, Beckmann SB, Salib M, Curovic VR, Beernink JM, Faivre A, Laverman GD, Wu Q, Bjornstad P, Hall AM, Rossing P, Fenton RA, Heerspink HJL, Hoorn EJ. Distinct proteomic signatures of urinary extracellular vesicles link to albuminuria and treatment responses in diabetic kidney disease. Kidney Int. 2026 Aug; 110(2):438-450.
Score: 0.014
-
Menon R, Kimmel PL, Otto EA, Subramanian L, O'Connor CL, Godfrey B, Smith C, Alakwaa F, Berthier CC, Sarwal MM, Woodle ES, Pyle L, Choi YJ, Ladd P, Sedor JR, Rosas SE, Waikar SS, Naik AS, Melo Ferreira R, Eadon MT, Bitzer M, Bjornstad P, Hodgin JB, Kretzler M, Kpmp FTKPMP. Not all reference samples are equal in single-cell transcriptomics of human kidney tissue. JCI Insight. 2026 Jul 22; 11(14).
Score: 0.014
-
Moedt E, Koshino A, Jongs N, Ju W, Nair V, Kretzler M, Hansen MK, Arnott CG, Wheeler DC, Rossing P, Coca SG, Hammarstedt A, Greasley PJ, Bjornstad P, Bakker SJL, Heerspink HJL. Association of Urinary EGF with Kidney Outcomes and Effects of Sodium-Glucose Cotransporter 2 Inhibition. J Am Soc Nephrol. 2026 Oct 01; 37(10):2210-2220.
Score: 0.014
-
Kwok R, Kishore K, Zafari T, Koye DN, Hachem M, de Boer IH, Jeong TD, Min WK, Porrini E, Bjornstad P, Tham YC, MacIsaac RJ, Churilov L, Ekinci EI. RenoTrue: A diabetes-specific machine learning model to estimate glomerular filtration rate for people with diabetes. Diabetes Res Clin Pract. 2026 Mar; 233:113137.
Score: 0.014
-
Cherney DZI, Belmar N, Bjornstad P, Chacko MM, Gunnarsson TP, Hodgin JB, Kretzler M, Pruijm M, Schytz PA, Tuttle KR. Rationale, design and baseline characteristics of REMODEL, a mechanism-of-action trial with semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol Dial Transplant. 2025 Oct 30; 40(11):2182-2192.
Score: 0.014
-
Thomas P, Missikpode C, Martinez OG, Verma A, Zhao R, Claudel SE, Schmidt IM, van Raalte DH, Bjornstad P, Layden BT, Lash JP, Waikar SS, Srivastava A. Association of Pancreas Volume With Adverse Clinical Outcomes. J Am Heart Assoc. 2025 Nov 04; 14(21):e042348.
Score: 0.014
-
Beernink JM, Jongs N, Mosterd CM, Scholtes RA, Caldwell-McGee A, Casillas D, Driscoll L, Greasley PJ, Karlsson C, Hammarstedt A, Sridhar VS, Muskiet MHA, Laverman GD, Cherney DZI, Bjornstad P, van Raalte DH, Heerspink HJL. Effects of dapagliflozin on sodium excretion, blood pressure and volume status in patients with type 2 diabetes and/or chronic kidney disease: The DAPASALT trial. Diabetes Obes Metab. 2025 08; 27(8):4415-4426.
Score: 0.013
-
van Baar MJB, Muskiet MHA, Scholtes RA, Touw DJ, Nieuwdorp M, Kramer MHH, Joles JA, Cherney DZI, Bjornstad P, Krebber MM, van Raalte DH. Fasting and postprandial kidney haemodynamic effects of empagliflozin and linagliptin in mono- and combination therapy compared to gliclazide in overweight people with type 2 diabetes (RACELINES): A randomised, double-blind trial. Diabetes Obes Metab. 2025 07; 27(7):3943-3956.
Score: 0.013
-
van Eeghen SA, Pyle L, Narongkiatikhun P, Choi YJ, Obeid W, Parikh CR, Vosters TG, van Valkengoed IG, Krebber MM, Touw DJ, den Heijer M, Bjornstad P, van Raalte DH, Nokoff NJ. Unveiling mechanisms underlying kidney function changes during sex hormone therapy. J Clin Invest. 2025 May 01; 135(9).
Score: 0.013
-
Kwok R, Kishore K, Zafari T, Koye DN, Hachem M, de Boer IH, Jeong TD, Min WK, Porrini E, Bjornstad P, MacIsaac RJ, Churilov L, Ekinci EI. Comparative performance of CKD-EPI equations in people with diabetes: An international pooled analysis of individual participant data. Diabetes Res Clin Pract. 2025 May; 223:112104.
Score: 0.013
-
Keller F, Denicolò S, Leierer J, Kruus M, Heinzel A, Kammer M, Ju W, Nair V, Burdet F, Ibberson M, Menon R, Otto E, Choi YJ, Pyle L, Ladd P, Bjornstad PM, Eder S, Rosivall L, Mark PB, Wiecek A, Heerspink HJL, Kretzler M, Oberbauer R, Mayer G, Perco P. Association of Urinary Epidermal Growth Factor, Fatty Acid-Binding Protein 3, and Vascular Cell Adhesion Molecule 1 Levels with the Progression of Early Diabetic Kidney Disease. Kidney Blood Press Res. 2024; 49(1):1013-1025.
Score: 0.013
-
Scarr D, Lovblom LE, Bjornstad P, Perkins BA, Kugathasan L, Cherney DZI, Lovshin JA. Estimated glomerular filtration rate calculated by serum creatinine lacks precision and accuracy in adults with type 2 diabetes with preserved renal function. J Diabetes Complications. 2023 09; 37(9):108562.
Score: 0.012
-
Sen T, Scholtes R, Greasley PJ, Cherney DZI, Dekkers CCJ, Vervloet M, Danser AHJ, Barbour SJ, Karlsson C, Hammarstedt A, Li Q, Laverman GD, Bjornstad P, van Raalte DH, Heerspink HJL. Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from DAPASALT and DIAMOND. Diabetes Obes Metab. 2022 08; 24(8):1578-1587.
Score: 0.011
-
van Velzen DM, Smits MM, van Bommel EJM, Muskiet MHA, Tonneijck L, Kramer MHH, Joles JA, den Heijer M, Nokoff N, Bjornstad P, van Raalte DH. Kidney hemodynamic function in men and postmenopausal women with type 2 diabetes and preserved kidney function. Am J Physiol Renal Physiol. 2021 06 01; 320(6):F1152-F1158.
Score: 0.010
-
Phadke G, Kaushal A, Tolan DR, Hahn K, Jensen T, Bjornstad P, Roncal-Jimenez C, Hernando AA, Lanaspa MA, Alexander MP, Kukla A, Johnson RJ. Osmotic Nephrosis and Acute Kidney Injury Associated With SGLT2 Inhibitor Use: A Case Report. Am J Kidney Dis. 2020 07; 76(1):144-147.
Score: 0.009
-
Sekercioglu N, Lovblom LE, Bjornstad P, Lovshin JA, Lytvyn Y, Boulet G, Farooqi MA, Orszag A, Lai V, Tse J, Cham L, Keenan HA, Brent MH, Paul N, Bril V, Perkins BA, Cherney DZI. Risk factors for diabetic kidney disease in adults with longstanding type 1 diabetes: results from the Canadian Study of Longevity in Diabetes. Ren Fail. 2019 Nov; 41(1):427-433.
Score: 0.009
-
van Bommel EJM, Ruiter D, Muskiet MHA, van Baar MJB, Kramer MHH, Nieuwdorp M, Joles JA, Bjornstad P, van Raalte DH. Insulin Sensitivity and Renal Hemodynamic Function in Metformin-Treated Adults With Type 2 Diabetes and Preserved Renal Function. Diabetes Care. 2020 01; 43(1):228-234.
Score: 0.009
-
Potier L, Roussel R, Marre M, Bjornstad P, Cherney DZ, El Boustany R, Fumeron F, Venteclef N, Gautier JF, Hadjadj S, Mohammedi K, Velho G. Plasma Copeptin and Risk of Lower-Extremity Amputation in Type 1 and Type 2 Diabetes. Diabetes Care. 2019 12; 42(12):2290-2297.
Score: 0.009
-
Al-Ozairi E, Rivard CJ, Sanchez Lozada LG, Lanaspa MA, Bjornstad P, Al Salem D, Alhubail A, Megahed A, Kuwabara M, Johnson RJ, Asad RA. Fructose tolerance test in obese people with and without type 2 diabetes. J Diabetes. 2020 Mar; 12(3):197-204.
Score: 0.009
-
van Raalte DH, Bjornstad P, Persson F, Powell DR, de Cassia Castro R, Wang PS, Liu M, Heerspink HJL, Cherney D. The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes. Diabetes Care. 2019 10; 42(10):1921-1929.
Score: 0.009
-
Scholtes RA, van Baar MJB, Lytvyn Y, Bjornstad P, Nieuwdorp M, Cherney DZI, van Raalte DH. Sodium glucose cotransporter (SGLT)-2 inhibitors: Do we need them for glucose-lowering, for cardiorenal protection or both? Diabetes Obes Metab. 2019 04; 21 Suppl 2:24-33.
Score: 0.009
-
Lytvyn Y, Bjornstad P, Lovshin JA, Singh SK, Boulet G, Farooqi MA, Lai V, Tse J, Cham L, Lovblom LE, Weisman A, Keenan HA, Brent MH, Paul N, Bril V, Advani A, Sochett E, Perkins BA, Cherney DZI. Association between uric acid, renal haemodynamics and arterial stiffness over the natural history of type 1 diabetes. Diabetes Obes Metab. 2019 06; 21(6):1388-1398.
Score: 0.009
-
Lytvyn Y, Bjornstad P, Lovshin JA, Boulet G, Farooqi MA, Lai V, Tse J, Cham L, Lovblom LE, Weisman A, Keenan HA, Brent MH, Paul N, Bril V, Advani A, Sochett E, Perkins BA, Cherney DZI. Renal Hemodynamic Function and RAAS Activation Over the Natural History of Type 1 Diabetes. Am J Kidney Dis. 2019 06; 73(6):786-796.
Score: 0.009
-
Lovshin JA, Lytvyn Y, Lovblom LE, Katz A, Boulet G, Bjornstad P, Lai V, Cham L, Tse J, Orszag A, Keenan HA, Paul N, Bril V, Wong DT, McReelis KD, Brent MH, Perkins BA, Cherney DZI. Retinopathy and RAAS Activation: Results From the Canadian Study of Longevity in Type 1 Diabetes. Diabetes Care. 2019 02; 42(2):273-280.
Score: 0.009
-
Lovshin JA, Bjornstad P, Lovblom LE, Bai JW, Lytvyn Y, Boulet G, Farooqi MA, Santiago S, Orszag A, Scarr D, Weisman A, Keenan HA, Brent MH, Paul N, Bril V, Perkins BA, Cherney DZI. Atherosclerosis and Microvascular Complications: Results From the Canadian Study of Longevity in Type 1 Diabetes. Diabetes Care. 2018 12; 41(12):2570-2578.
Score: 0.008
-
Tonneijck L, Muskiet MHA, Smits MM, Bjornstad P, Kramer MHH, Diamant M, Hoorn EJ, Joles JA, van Raalte DH. Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials. Diabetes Obes Metab. 2018 05; 20(5):1235-1245.
Score: 0.008
-
Lovshin JA, Boulet G, Lytvyn Y, Lovblom LE, Bjornstad P, Farooqi MA, Lai V, Cham L, Tse J, Orszag A, Scarr D, Weisman A, Keenan HA, Brent MH, Paul N, Bril V, Perkins BA, Cherney DZ. Renin-angiotensin-aldosterone system activation in long-standing type 1 diabetes. JCI Insight. 2018 01 11; 3(1).
Score: 0.008
-
Kuwabara M, Hisatome I, Niwa K, Hara S, Roncal-Jimenez CA, Bjornstad P, Nakagawa T, Andres-Hernando A, Sato Y, Jensen T, Garcia G, Rodriguez-Iturbe B, Ohno M, Lanaspa MA, Johnson RJ. Uric Acid Is a Strong Risk Marker for Developing Hypertension From Prehypertension: A 5-Year Japanese Cohort Study. Hypertension. 2018 01; 71(1):78-86.
Score: 0.008
-
Kuwabara M, Niwa K, Hisatome I, Nakagawa T, Roncal-Jimenez CA, Andres-Hernando A, Bjornstad P, Jensen T, Sato Y, Milagres T, Garcia G, Ohno M, Lanaspa MA, Johnson RJ. Asymptomatic Hyperuricemia Without Comorbidities Predicts Cardiometabolic Diseases: Five-Year Japanese Cohort Study. Hypertension. 2017 06; 69(6):1036-1044.
Score: 0.008
-
Kuwabara M, Bjornstad P, Hisatome I, Niwa K, Roncal-Jimenez CA, Andres-Hernando A, Jensen T, Milagres T, Sato Y, Garcia G, Ohno M, Lanaspa MA, Johnson RJ. Elevated Serum Uric Acid Level Predicts Rapid Decline in Kidney Function. Am J Nephrol. 2017; 45(4):330-337.
Score: 0.008
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|